Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 379,500 shares, a growth of 600.2% from the March 31st total of 54,200 shares. Approximately 4.4% of the shares of the stock are sold short. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is currently 0.3 days.

Xilio Therapeutics Trading Up 7.9 %

XLO opened at $1.09 on Friday. The firm has a market capitalization of $37.57 million, a PE ratio of -0.39 and a beta of -0.12. The firm’s 50-day moving average price is $0.92 and its 200 day moving average price is $1.03. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.40.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Monday, April 1st. The company reported ($0.64) earnings per share for the quarter. As a group, analysts predict that Xilio Therapeutics will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. purchased 485,250 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were purchased at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the transaction, the insider now owns 7,345,473 shares of the company’s stock, valued at approximately $5,582,559.48. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. PFG Investments LLC acquired a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.